Investor Presentaiton
Hematology
Reblozyl BET Inhibitor
Breyanzi golcadomide Abecma
alnuctamab
GPRC5D
Best-in-class CAR T across the broadest array of B-cell
malignancies
01
02
•
•
Best-in-class CAR T with the
broadest label in 2L+ LBCL
Differentiated efficacy
& safety profile
TRANSCEND-CLL: First
& only pivotal trial in
high-risk R/R CLL/SLL
Demonstrated deep and
durable responses
LBCL
Large B-Cell
Lymphoma
MCL
Mantle Cell
Lymphoma
Aggressive
Rapidly progressive but responsive
to chemotherapy and often curable
Bristol Myers Squibb™
CLL/SLL
Chronic Lymphocytic Leukemia/
Small Lymphocytic Lymphoma
.
03
iber/mezi
Potential best-in-disease in
R/R FL
Unprecedented data in
additional lymphoma types
including R/R MCL
FL
Follicular
Lymphoma
MZL
Marginal Zone
Lymphoma
Indolent
Slowly progressive and responsive to therapy but
not typically curable with standard approaches
Not for Product Promotional Use
79View entire presentation